Adalimumab
Treatment for Ankylosing Spondylitis
Typical Dosage: 40mg every other week subcutaneous
Effectiveness
65%
Safety Score
60%
Clinical Trials
68
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
40mg every other week subcutaneous
Time to Effect
2-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$500
Side Effect Mgmt:$500
Total Annual:$31,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$47,692
Cost per Remission
$124,000
Comparison vs NSAIDs (optimized)
Cost Difference
+$30,600/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Adalimumab Outcomes
for Ankylosing Spondylitis
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+65%
Remission Rate
+25%
Common Side Effects
Injection site reactions
+15%
Upper respiratory tract infections
+25%
Sinusitis
+10%
Urinary tract infection
+5%
Serious infections
+3%
Reactivation of latent TB/Hepatitis B
+0.5%
Sources:
Active Clinical Trials
2 active trials recruiting for Adalimumab in Ankylosing Spondylitis
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT06833112NOT YET RECRUITINGPHASE4
10 participants
INTERVENTIONAL
Guiyang, China
Started: Feb 1, 2025
A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
NCT06242652ACTIVE NOT RECRUITINGPHASE2
250 participants
INTERVENTIONAL
Beijing, China
Started: Mar 19, 2024
Completed Clinical Trials
12 completed trials for Adalimumab in Ankylosing Spondylitis
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
NCT02333383COMPLETED
201 participants
OBSERVATIONAL
Started: Dec 31, 2014
A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
NCT00667355COMPLETEDPHASE3
41 participants
INTERVENTIONAL
Aichi, Japan +18 more
Started: Feb 1, 2008
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
NCT04135508COMPLETEDPHASE3
554 participants
INTERVENTIONAL
Started: Dec 13, 2016
Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA
NCT03561649COMPLETEDNA
50 participants
INTERVENTIONAL
Belfort, France +4 more
Started: Jun 14, 2018
Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
NCT02492217COMPLETEDPHASE4
69 participants
INTERVENTIONAL
Lisbon, Portugal
Started: May 1, 2015
Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)
NCT01895764COMPLETEDPHASE4
110 participants
INTERVENTIONAL
Blois, France +10 more
Started: Mar 20, 2013
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
NCT01114880COMPLETEDPHASE3
344 participants
INTERVENTIONAL
Hefei, China +8 more
Started: Jan 1, 2010
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
NCT00195819COMPLETEDPHASE3
82 participants
INTERVENTIONAL
Calgary, Canada +8 more
Started: Dec 1, 2003
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
NCT00478660COMPLETEDPHASE3
1.25K participants
INTERVENTIONAL
Graz, Austria +204 more
Started: Feb 1, 2006
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
NCT00085644COMPLETEDPHASE3
315 participants
INTERVENTIONAL
Birmingham, United States +21 more
Started: Jan 1, 2004
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
NCT03259074COMPLETEDPHASE3
859 participants
INTERVENTIONAL
Mesa, United States +170 more
Started: Nov 30, 2017
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
NCT01329380COMPLETED
403 participants
OBSERVATIONAL
Nagoya, Japan +193 more
Started: Oct 27, 2010
Showing 20 of 68 total trials